Growth & profitability
- Revenue has grown 41.7% per year over the past 2 years.
- Operating margin has contracted, at -92.9% in the latest year.
3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $588M | -$528M | 79.6% | -92.9% | $171M | — | $208M |
| 2024 | $390M | -$12M | 76.8% | -8.2% | $48M | — | $301M |
| 2023 | $293M | -$108M | 66.3% | -44.6% | -$66M | — | $235M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $182M | $35M | 84.6% | 17.6% | $43M | — | $187M |
| Dec '25 | $171M | $32M | 84.4% | 16.0% | $63M | — | $208M |
| Sep '25 | $154M | -$2M | 81.8% | -4.0% | $82M | — | $261M |
| Jun '25 | $139M | -$576M | 70.3% | -417.5% | — | — | $237M |
| Mar '25 | $124M | $17M | 80.9% | 10.6% | $5M | — | $288M |
| Dec '24 | $117M | $27M | 81.9% | 17.8% | $38M | — | $301M |
| Sep '24 | $101M | $341000 | 78.8% | -3.8% | $28M | — | $268M |
| Jun '24 | $90M | -$13M | 74.2% | -19.5% | — | — | $237M |
| Mar '24 | — | -$26M | — | — | — | — | — |
How the market has priced HNGE against its own fundamentals since 2025-05 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Hinge Health, Inc.'s revenue has grown 41.7% per year. These are computed facts, not advice.
As of FY2025, Hinge Health, Inc. reported — of total debt against $208M of cash.
In FY2025, gross margin was 79.6%, operating margin -92.9%, and net margin -89.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.